Indivior Pharmaceuticals, Inc. Deferred Tax Relating To Items Charged Or Credited Directly To Equity
Indivior Pharmaceuticals, Inc. (INDV) reported Deferred Tax Relating To Items Charged Or Credited Directly To Equity of -$19.00 million for the 12-month period ending 2023-12-31, per its 20-F filed 2024-03-06.
Discontinued › Expense Statement › Operating Expenses
ifrs-full:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity · last filed 2024-03-06
| Period end | Deferred Tax Relating To Items Charged Or Credited Directly To Equity 12 month |
|---|---|
| 2023-12-31 | -$19.00M 20-F · filed 2024-03-06 |
| 2022-12-31 | $9.00M 20-F · filed 2024-03-06 |
| 2021-12-31 | $13.00M 20-F · filed 2024-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |